DENTAID Instituto de Investigación Sanitaria Aragón **RESEARCI** CENTER Sevilla Sepa21

RANDOMISED CLINICAL TRIAL TO ASSESS THE IMPACT OF ORAL INTERVENTION WITH CETYLPYRIDINIUM CHLORIDE TO REDUCE SARS-COV-2 VIRAL LOAD

Tarrago Gil, Rosa (IP) (1); Aza Pascual-Salcedo, Mercedes (2); Lallana Alvarez, María Jesús (2); Serrano Peris, Diana (3); Millán Fernández, Yolanda (1); Refusta Ainaga, Raquel (4); Fuentes Viñuales, Roberto (4); Bueno Sancho, Jessica (5); Algarate Cajo, Sonia (5); Millán Sobrino, Estela (6).

(1) Dental hygienist, Aragones health Service (Ministry of Health) Aragon Research Institute(IIS Aragón) Zaragoza (SPAIN) rmtarrago@salud.aragon.es (2) Pharmacist (Ministry of Health). (3) Physician (Ministry of Health). (4) Nurse (Ministry of Health). (5) Microbiologist (Ministry of Health) Lozano Blesa University Clinical Hospital(6) Dentist (Ministry of Health).



The oral cavity represents a potential source of SARS-CoV2 infection. SARS-CoV-2 binds to the receptors of angiotensin-converting enzyme 2 and the transmembrane protease serine 2 enzyme, which are highly expressed in the salivary glands, tongue and sulcular epithelium. The intervention, aimed at reducing the viral load in saliva through rinsing, may help control and reduce viral transmission and could be considered as a novel Public Health strategy.





To determine the efficacy of cetylpyridinium chloride (CPC) mouthwashes in reducing the viral load of SARS-CoV-2 in the saliva of COVID-19 patients.





80 SARS-CoV-2-positive patients were enrolled and randomly assigned to two groups: CPC intervention group (n = 40) and water control group (n = 40). Inclusion criteria: SARS-CoV-2 -positive patients Symptom development up to 3 days, 18-80 years of age. Exclusion criteria: Patients with hyposialia. Patients who had used oral antiseptics (in the form of mouthwash containing CPC, rinses with povidone iodine, mouthwashes with alcohol and essential oils) and/or toothpastes with CPC in the month prior. Patients with cognitive and/or motor impairment. Pregnant women. Saliva samples were collected from the patients at the time of diagnosis and 2 hours after the application of CPC/water rinses. The samples were subjected to RT-PCR and ELISA assay.

The clinical trial was approved by the Clinical Research Ethics Committee of Aragon with the C.P. reference **CPC01- C.I.** (Research Committee) EC20/0092. It was registered on the ClinicalTrials.gov platform under reference number NCT04820803.





The average age of the patients was **48.6 years** (SD = 18.2) and 60% were male, with no statistically significant differences between the two groups.



RT-PCR analysis using the ORF1ab sequence as a target; no statistically significant differences were observed when comparing the Ct values of both groups (WATER vs CPC) either at baseline (M1) or 2 hours after rinsing (M2).



GROUP Mean (SD) IQR p-value 22.56 (3.85) 22.80 (4.40) 0.4771 23.45 (4.25) WATER 22.82 (5.04) 22.59 (3.19) 23.40 (4.25) 0.6696 WATER 22.71 (5.08) 22.95 (5.43)

Analysis with the ELISA technique, no significant baseline differences were observed between the CPC and WATER groups at baseline (0 hours).



RT-PCR analysis using the N gene as a target; no statistically significant differences were observed in this care either when comparing the Ct values of both groups (WATER vs CPC) either at baseline (M1) or 2 hours after rinsing (M2).



However, with the ELISA technique, 2h after rinsing, a significantly higher amount of nucleocapsids was observed in the CPC group compared to the control group.





Statistically significant differences were observed between the ELISA values measured at baseline and 2h after rinsing. The effect size is larger in the CPC group.



The use of 0.07% CPC mouthwashes causes the degradation of the SARS-CoV-2 virus in the mouth of COVID-19-positive patients. The use of CPC mouthwashes can be useful to reduce viral load, which could help to decrease the transmission of the virus and lessen the symptoms of COVID-19.

